Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John M Davis

Showing results (121-130 of 505) with videos related to

Pageof 51
Sort By:
The Journal of Surgical Research|March 4, 2019
Starting Line for Scholarly Activity in New Residency Programs: Lessons Learned for Institutional SuccessJason D Sciarretta, Christine D Atchison, Ayolola O Onayemi, et al.
Arthritis Care & Research|April 20, 2012
Contribution of obesity to the rise in incidence of rheumatoid arthritisCynthia S Crowson, Eric L Matteson, John M Davis, et al.
The Lancet. Psychiatry|October 1, 2023
Antipsychotic dose reduction: unclear benefits but certain risksStefan Leucht, Irene Bighelli, Spyridon Siafis, et al.
BMC Nephrology|July 16, 2013
Predictors of renal recovery in patients with pre-orthotopic liver transplant (OLT) renal dysfunctionJose Iglesias, Elliot Frank, Sushil Mehandru, et al.
Lancet (London, England)|December 10, 2013
Efficacy of antipsychotic drugs for schizophrenia - Authors' replyStefan Leucht, Andrea Cipriani, John R Geddes, et al.
Pharmacology Research & Perspectives|June 29, 2018
Potential role for histone deacetylation in chronic diazepam-induced downregulation of α1-GABA<sub>A</sub> receptor subunit expressionJames Auta, Eleonora Gatta, John M Davis, et al.
Current Issues in Molecular Biology|April 27, 2026
From Molecules to Meaning: Integrating Neuropeptides, Sociostasis, and Hormesis in the Brain-Heart AxisHans P Nazarloo, Stephen W Porges, John M Davis, et al.
Journal of Clinical Psychopharmacology|February 15, 2017
Should Antipsychotic Medications for Schizophrenia Be Given for a Lifetime?: A Naturalistic, Long-Term Follow-Up StudyIra D Glick, John M Davis, Daisy Zamora, et al.
Philosophy, Ethics, and Humanities in Medicine : PEHM|May 17, 2011
Should we treat depression with drugs or psychological interventions? A reply to IoannidisJohn M Davis, William J Giakas, Jie Qu, et al.
Journal of Clinical Psychopharmacology|July 16, 2008
Antipsychotic withdrawal-induced relapse predicts future relapses in institutionalized adults with severe intellectual disabilityDavid S Janowsky, L Jarrett Barnhill, Abdul S Khalid, et al.
Pageof 51

Showing results (121-130 of 505) with videos related to

Sort By:
Pageof 51
The Journal of Surgical Research|March 4, 2019
Starting Line for Scholarly Activity in New Residency Programs: Lessons Learned for Institutional SuccessJason D Sciarretta, Christine D Atchison, Ayolola O Onayemi, et al.
Arthritis Care & Research|April 20, 2012
Contribution of obesity to the rise in incidence of rheumatoid arthritisCynthia S Crowson, Eric L Matteson, John M Davis, et al.
The Lancet. Psychiatry|October 1, 2023
Antipsychotic dose reduction: unclear benefits but certain risksStefan Leucht, Irene Bighelli, Spyridon Siafis, et al.
BMC Nephrology|July 16, 2013
Predictors of renal recovery in patients with pre-orthotopic liver transplant (OLT) renal dysfunctionJose Iglesias, Elliot Frank, Sushil Mehandru, et al.
Lancet (London, England)|December 10, 2013
Efficacy of antipsychotic drugs for schizophrenia - Authors' replyStefan Leucht, Andrea Cipriani, John R Geddes, et al.
Pharmacology Research & Perspectives|June 29, 2018
Potential role for histone deacetylation in chronic diazepam-induced downregulation of α1-GABA<sub>A</sub> receptor subunit expressionJames Auta, Eleonora Gatta, John M Davis, et al.
Current Issues in Molecular Biology|April 27, 2026
From Molecules to Meaning: Integrating Neuropeptides, Sociostasis, and Hormesis in the Brain-Heart AxisHans P Nazarloo, Stephen W Porges, John M Davis, et al.
Journal of Clinical Psychopharmacology|February 15, 2017
Should Antipsychotic Medications for Schizophrenia Be Given for a Lifetime?: A Naturalistic, Long-Term Follow-Up StudyIra D Glick, John M Davis, Daisy Zamora, et al.
Philosophy, Ethics, and Humanities in Medicine : PEHM|May 17, 2011
Should we treat depression with drugs or psychological interventions? A reply to IoannidisJohn M Davis, William J Giakas, Jie Qu, et al.
Journal of Clinical Psychopharmacology|July 16, 2008
Antipsychotic withdrawal-induced relapse predicts future relapses in institutionalized adults with severe intellectual disabilityDavid S Janowsky, L Jarrett Barnhill, Abdul S Khalid, et al.
Pageof 51